{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:48:18Z","timestamp":1788871698006,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,6,30]],"date-time":"2015-06-30T00:00:00Z","timestamp":1435622400000},"content-version":"vor","delay-in-days":637,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"German Jos\u00e9 Carreras Leukaemia Foundation"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.bbmt.2013.07.001","type":"journal-article","created":{"date-parts":[[2013,7,8]],"date-time":"2013-07-08T23:06:40Z","timestamp":1373324800000},"page":"1439-1445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Distinct Deleterious Effects of Cyclosporine and Tacrolimus and Combined Tacrolimus\u2013Sirolimus on Endothelial Cells: Protective Effect of Defibrotide"],"prefix":"10.1016","volume":"19","author":[{"given":"Alba","family":"Carmona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maribel","family":"D\u00edaz-Ricart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Palomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gin\u00e9s","family":"Escolar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enric","family":"Carreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2013.07.001_bib1","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/bmt.2011.65","article-title":"The role of the endothelium in the short-term complications of hematopoietic SCT","volume":"46","author":"Carreras","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.07.001_bib2","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.bbmt.2009.01.013","article-title":"The release of soluble factors contributing to endothelial activation and damage after hematopoietic stem cell transplantation is not limited to the allogeneic setting and involves several pathogenic mechanisms","volume":"15","author":"Palomo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.07.001_bib3","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.bbmt.2010.02.008","article-title":"Endothelial dysfunction after hematopoietic stem cell transplantation: Role of the conditioning regimen and the type of transplantation","volume":"16","author":"Palomo","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.07.001_bib4","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.bbmt.2010.11.019","article-title":"Defibrotide prevents the activation of macrovascular and microvascular endothelia caused by soluble factors released to blood by autologous hematopoietic stem cell transplantation","volume":"17","author":"Palomo","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.07.001_bib5","first-page":"578","article-title":"Granulocyte colony-stimulating factor increases expression of adhesion receptors on endothelial cells through activation of p38 MAPK","volume":"89","author":"Fuste","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2013.07.001_bib6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1161\/01.RES.74.3.477","article-title":"Mechanisms of the endothelial toxicity of cyclosporine A. Role of nitric oxide, cGMP, and Ca2+","volume":"74","author":"Gallego","year":"1994","journal-title":"Circ Res"},{"key":"10.1016\/j.bbmt.2013.07.001_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0272-6386(96)90126-2","article-title":"Cyclosporine enhances leukocyte adhesion to vascular endothelium under physiologic flow conditions","volume":"28","author":"Gallego","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.bbmt.2013.07.001_bib8","doi-asserted-by":"crossref","first-page":"35605","DOI":"10.1074\/jbc.M205826200","article-title":"Cyclosporine A enhances leukocyte binding by human intestinal microvascular endothelial cells through inhibition of p38 MAPK and iNOS. Paradoxical proinflammatory effect on the microvascular endothelium","volume":"277","author":"Rafiee","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.bbmt.2013.07.001_bib9","first-page":"57","article-title":"Surgical biology for the clinician: Vascular effects of immunosuppression","volume":"53","author":"Tepperman","year":"2010","journal-title":"Can J Surg"},{"key":"10.1016\/j.bbmt.2013.07.001_bib10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00005344-200501000-00014","article-title":"The impact of immunosuppression on endothelial function","volume":"45","author":"Trapp","year":"2005","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"issue":"3 Suppl.","key":"10.1016\/j.bbmt.2013.07.001_bib11","doi-asserted-by":"crossref","first-page":"118S","DOI":"10.1016\/S0041-1345(03)00218-5","article-title":"Minimizing calcineurin inhibitor drugs in renal transplantation","volume":"35","author":"Flechner","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bbmt.2013.07.001_bib12","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3324\/haematol.12949","article-title":"Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: A retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation","volume":"93","author":"Tichelli","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2013.07.001_bib13","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/pbc.22861","article-title":"Transplant-associated thrombotic microangiopathy in pediatric patients treated with sirolimus and tacrolimus","volume":"57","author":"Rosenthal","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2013.07.001_bib14","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.bbmt.2012.10.006","article-title":"Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus\/sirolimus-based graft-versus-host disease prophylaxis","volume":"19","author":"Shayani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.07.001_bib15","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3324\/haematol.2012.065599","article-title":"The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate","volume":"98","author":"Perez-Sim\u00f3n","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2013.07.001_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bbmt.2008.11.004","article-title":"Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: Results of the EVTAC trial","volume":"15","author":"Platzbecker","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.07.001_bib17","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1182\/blood-2008-07-169342","article-title":"Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation","volume":"112","author":"Cutler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.07.001_bib18","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/1523-1747.ep12613748","article-title":"HMEC-1: Establishment of an immortalized human microvascular endothelial cell line","volume":"99","author":"Ades","year":"1992","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.bbmt.2013.07.001_bib19","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood-2002-04-1216","article-title":"Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: Response without significant toxicity in a high-risk population and factors predictive of outcome","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.07.001_bib20","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/sj.leu.2403004","article-title":"Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells","volume":"17","author":"Falanga","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2013.07.001_bib21","doi-asserted-by":"crossref","first-page":"686","DOI":"10.4161\/cbt.6.5.3959","article-title":"Defibrotide: An endothelium protecting and stabilizing drug, has an anti-angiogenic potential in\u00a0vitro and in\u00a0vivo","volume":"6","author":"Koehl","year":"2007","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.bbmt.2013.07.001_bib22","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1161\/01.ATV.16.7.883","article-title":"Antibodies to CD36 (GPIV) inhibit platelet adhesion to subendothelial surfaces under flow conditions","volume":"16","author":"Diaz-Ricart","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.bbmt.2013.07.001_bib23","first-page":"195","article-title":"Automated microdensitometry and protein assays as a measure for platelet adhesion and aggregation on collagen-coated slides under controlled flow conditions","volume":"95","author":"Muggli","year":"1980","journal-title":"J\u00a0Lab Clin Med"},{"key":"10.1016\/j.bbmt.2013.07.001_bib24","first-page":"522","article-title":"A\u00a0perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix, and purified components","volume":"102","author":"Sakariassen","year":"1983","journal-title":"J\u00a0Lab Clin Med"},{"key":"10.1016\/j.bbmt.2013.07.001_bib25","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1160\/TH08-12-0810","article-title":"Serotonergic mechanisms enhance platelet-mediated thrombogenicity","volume":"102","author":"Galan","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.bbmt.2013.07.001_bib26","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/ndt\/gfr261","article-title":"Sirolimus-based regimen is associated with decreased expression of glomerular vascular endothelial growth factor","volume":"27","author":"Vuiblet","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.bbmt.2013.07.001_bib27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1432-2277.2004.tb00377.x","article-title":"Differential effects of modern immunosuppressive agents on the development of intimal hyperplasia","volume":"17","author":"Waller","year":"2004","journal-title":"Transplant Int"},{"key":"10.1016\/j.bbmt.2013.07.001_bib28","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1136\/hrt.2009.172379","article-title":"Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results","volume":"95","author":"Byrne","year":"2009","journal-title":"Heart"},{"key":"10.1016\/j.bbmt.2013.07.001_bib29","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa012843","volume":"346","author":"Morice","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2013.07.001_bib30","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2165\/00003495-200363120-00006","article-title":"Tacrolimus: A further update of its use in the management of organ transplantation","volume":"63","author":"Scott","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.bbmt.2013.07.001_bib31","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1517\/14656566.9.4.635","article-title":"The role of tacrolimus in renal transplantation","volume":"9","author":"Bowman","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.bbmt.2013.07.001_bib32","first-page":"2303","article-title":"Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation","volume":"92","author":"Ratanatharathorn","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.07.001_bib33","first-page":"2062","article-title":"Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors","volume":"96","author":"Nash","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.07.001_bib34","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1034\/j.1399-0012.17.s9.1.x","article-title":"Morphological and biochemical effects of immunosuppressive drugs in a capillary tube assay for endothelial dysfunction","volume":"17","author":"Wilasrusmee","year":"2003","journal-title":"Clin Transplant"},{"key":"10.1016\/j.bbmt.2013.07.001_bib35","doi-asserted-by":"crossref","first-page":"E261","DOI":"10.1111\/j.1399-3046.2011.01601.x","article-title":"Successful sirolimus rescue in tacrolimus-induced thrombotic microangiopathy after living-related liver transplantation","volume":"16","author":"Czubkowski","year":"2012","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.bbmt.2013.07.001_bib36","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1182\/blood-2009-03-207563","article-title":"A\u00a0phase II pilot study of\u00a0tacrolimus\/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens","volume":"115","author":"Rodriguez","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.07.001_bib37","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1600-0609.2011.01685.x","article-title":"Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders","volume":"87","author":"Ringd\u00e9n","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2013.07.001_bib38","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/ki.2010.492","article-title":"Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: A randomized, controlled Spare-the-Nephron trial","volume":"79","author":"Weir","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.bbmt.2013.07.001_bib39","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/bmt.2011.104","article-title":"Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation","volume":"47","author":"Johnston","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.07.001_bib40","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","article-title":"Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: An open-label, phase 3, randomised controlled trial","volume":"379","author":"Corbacioglu","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2013.07.001_bib41","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1089\/oli.2006.16.105","article-title":"Defibrotide, a polydisperse mixture of single-stranded phosphodiester oligonucleotides with lifesaving activity in severe hepatic veno-occlusive disease: Clinical outcomes and potential mechanisms of action","volume":"16","author":"Kornblum","year":"2006","journal-title":"Oligonucleotides"},{"key":"10.1016\/j.bbmt.2013.07.001_bib42","first-page":"1122","article-title":"Defibrotide for the treatment of\u00a0hepatic veno-occlusive disease: Results of the European compassionate-use study","volume":"111","author":"Chopra","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2013.07.001_bib43","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.bbmt.2010.02.009","article-title":"Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: A multicenter, randomized, dose-finding trial","volume":"16","author":"Richardson","year":"2010","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879113002954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879113002954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:45:24Z","timestamp":1761057924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879113002954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S1083879113002954"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2013.07.001","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct Deleterious Effects of Cyclosporine and Tacrolimus and Combined Tacrolimus\u2013Sirolimus on Endothelial Cells: Protective Effect of Defibrotide","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2013.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}